Clinical trials in pharmacogenetics and pharmacogenomics: Methods and applications

American Journal of Health-System Pharmacy

Volumn 57, Issue 9, 2000, Pages 887-901

  Rioux, Patrice P ^a  

^a Clin Pharmacogenomics P   (United States)

Author keywords

Clinical studies; Drug administration; Drugs; Ethics; Food and Drug Administration (U.S.); Pharmacogenetics; Product development; Regulations; Toxicity

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; MERCAPTOPURINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; STEROID 11BETA MONOOXYGENASE; SUBSTANCE P ANTAGONIST; THIOPURINE METHYLTRANSFERASE; WARFARIN;

CLINICAL TRIAL; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; ETHICS; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0034192322     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.9.887     Document Type: Review

References (31)

1. Weber WW. Pharmacogcnetics. New York: Oxford Univ. Press; 1997:344.
2. Houseman D, Ledley F. Why pharmacogenomics? Why now? Nature Biotech. 1998; 16(suppl):2-3. Editorial.
3. Gelernter I, Cubells IF, Kidd JR et al. Population studies of polymorphisms of the serotonin transporter protein gene. Am J Med Genet. 1999; 88(1):61-6.
4. Hardy GH. Mendelian proportions in a mixed population. Science. 1908; 28:49-50.
5. Leathart JBS, London SJ, Steward A et al. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics. 1998; 8:529-41.
6. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil induced toxicity. J Clin Invest. 1988; 81:47-51.
7. Milano G, Etienne MC, Pierrefite V et al. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer. 1999; 79:627-30.
8. Van Kuilenburg ABP, van Lenthe H, Blom MJ et al. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer. 1999; 79:620-6.
9. Wei X, McLeod HL, McMurrough I et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996; 98:610-5.
10. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980; 32:651-62.
11. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol. 1998; 125:879-87.
12. Kuivenhoven JA, Jukema JW, Zwinderman AH et al., for the Regression Growth Evaluation Statin Study Group. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med. 1998; 338:86-93.
13. Rigat B, Hubert C, Alhenc-Gelas F et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86:1343-6.
14. Todd GP, Chadwick IG, Higgins KS et al. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol. 1995; 39:131-4.
15. Ueda S, Meredith PA, Morton JI et al. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation. 1998;98:2148-53.
16. O'Toole L, Stewart M, Padfield P et al. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol. 1998; 32:988-94.
17. Lesch KP, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274:1527-31.
18. Smeraldi E, Zanardi R, Benedetti F et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998; 3:508-11.
19. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry. 1998; 59(suppl 5):16-23.
20. Aithal GP, Day CP, Kesteven PJE et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1998; 353:717-9.
21. McLeod HL, Pritchard SC, Githang'a J et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele speificity in Caucasian and Kenyan individuals. Pharmacogenetics. 1999; 9:773-6.
22. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine 5-methyltransferase gene locus. J Natl Cancer Inst. 1999; 91:2001-8.
23. Kramer MS, Cutler N, Feighner J et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998; 281:1640-5.
24. Snider RM, Constantine JW, Lowe JA III et al. A potent nonpeptide antagonist of the substance P (NKI) receptor. Science. 1991; 251:435-7.
25. Arinami T, Li E, Mitsushio H et al. An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders. Biol Psychiatry. 1996; 40:1122-7.
26. Elston RC, Idury RM, Cardon ER et al. The study of candidate genes in drug trials: sample size considerations. Stat Med. 1999; 18:741-51.
27. Merz JF, Leonard DGB, Miller ER. IRB review and consent in human tissue research. Science. 1999; 283:1647-8.
28. Farlow MR, Lahiri DK, Poirier J et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 1998; 50:669-77.
29. Menard S, Tagliabue E, Campiglio M et al. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol. 2000; 182:150-62.
30. Support for non-competitive trials. Lancet. 1999; 353:855. Editorial.
31. Basilion J, Schievella A, Burns E et al. Selective killing of cancer cells based on loss of heterozygosity and normal variation in the human genome: a new paradigm for anti-cancer drug therapy. Mol Pharmacol. 1999; 56:359-69.